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Available online 28 February 2016Ceramide accumulation is known to accompany acute myocardial ischemia, but its role in the pathogenesis of is-
chemic heart disease is unclear. In this study, we aimed to determine how ceramides accumulate in the ischemic
heart and to determine if cardiac function following ischemia can be improved by reducing ceramide
accumulation.
To investigate the association between ceramide accumulation and heart function,we analyzedmyocardial left ven-
tricle biopsies from subjects with chronic ischemia and found that ceramide levels were higher in biopsies from
subjects with reduced heart function. Ceramides are produced by either de novo synthesis or hydrolysis of
sphingomyelin catalyzedby acid and/or neutral sphingomyelinase.Weused culturedHL-1 cardiomyocytes to inves-
tigate these pathways and showed that acid sphingomyelinase activity rather than neutral sphingomyelinase activ-
ity or de novo sphingolipid synthesiswas important for hypoxia-induced ceramide accumulation.We also usedmice
with a partial deﬁciency in acid sphingomyelinase (Smpd1+/−mice) to investigate if limiting ceramide accumula-
tion under ischemic conditions would have a beneﬁcial effect on heart function and survival. Although we showed
that cardiac ceramide accumulationwas reduced in Smpd1+/−mice 24h after an inducedmyocardial infarction, this
reduction was not accompanied by an improvement in heart function or survival.
Our ﬁndings show that accumulation of cardiac ceramides in the post-ischemic heart is mediated by acid
sphingomyelinase. However, targeting ceramide accumulation in the ischemic heart may not be a beneﬁcial
treatment strategy.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Myocardial ischemia1. Introduction
Ceramides are recognized not only as structural components of
cellular membranes but also as bioactive lipids. These bioactive lipids
may promote cellular stress responses such as inﬂammation,mitochon-
drial dysfunction, apoptosis and defects in insulin signaling [1].
Ceramides consist of a sphingosine base linked to a fatty acid and are
produced either by de novo synthesis (from palmitate via the precursor
dihydroceramides) or hydrolysis of sphingomyelin [2].
Abnormal ceramide accumulation has recently been implicated in
acutemyocardial ischemia [3,4]. Increasing evidence indicates thatmet-
abolic reprogramming in the ischemic heart contributes to pathological
cardiac remodeling, leading to increased incidence of heart failure [5].
However, it is not known if myocardial ceramide accumulation plays a
role in this process. Here, we investigated how ceramides accumulate
and what role they play in the pathogenesis of myocardial ischemia.. This is an open access article under2. Material and methods
Material and methods are described in the Supplemental material.
3. Results
To investigate the association between ceramide accumulation and
heart function, we analyzedmyocardial left ventricle biopsies from sub-
jects with chronic ischemia and found that ceramide levels were higher
in biopsies from subjects with reduced heart function (Fig. 1A). Further-
more, total triglycerides correlated with dihydroceramides (an up-
stream precursor to ceramides and a marker of de novo sphingolipid
synthesis), indicating that increased accumulation of neutral lipids
correlates with increased de novo sphingolipid synthesis. However,
triglycerides did not correlate with ceramides (Fig. 1B), suggesting
that myocardial ceramide accumulation in the post-ischemic human
heart is disassociated from accumulation of neutral lipids and of the
sphingolipid de novo synthesis pathway (see Fig. 1C for proposed path-
way). Thus, our results suggest that cardiac ceramides accumulatethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Ceramides correlate with heart function and hypoxia-induced ceramide accumulation in cardiomyocytes is mediated by acid sphingomyelinase. (A) Ceramide concentrations in
heart biopsies from patients with chronic cardiac ischemia and ejection fraction (EF) N 55% or b45% (n = 30). ⁎P b 0.05, vs EF N 55%. (B) Correlations between ceramides and
dihydroceramides with triglycerides in heart biopsies from patients with chronic cardiac ischemia (n = 30). (C) Ceramide synthesis pathway. (D) Hypoxia-induced ceramide
accumulation in HL-1 cardiomyocytes. HL-1 cells were incubated in normoxia or hypoxia for 2 h or 8 h and dihydroceramides and ceramides were measured with HPLC and mass
spectrometry. (n = 3). Data are shown as mean ± SEM, ⁎⁎⁎P b 0.001 vs normoxia. (E) Incorporation of deuterium-labelled serine into dihydroceramides and ceramides in HL-1
cardiomyocytes following incubation in normoxia or hypoxia for 2 h or 8 h (n = 3) ⁎⁎⁎P b 0.001 vs normoxia. (F) Ceramide levels in HL-1 cardiomyocytes transfected with control
siRNA, Smpd1 siRNA (ID #1 and #2) and Smpd2 siRNA (ID #1 and #2), incubated in normoxia or hypoxia for 24 h (n= 3–6). Data are mean ± SEM.
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they associate with heart function in the post-ischemic heart.
We further investigated how hypoxia induces ceramide accu-
mulation using cultured HL-1 cardiomyocytes. Levels of ceramides and
dihydroceramides were upregulated by hypoxia in HL-1 cardiomyocytes
(Fig. 1D). We next incubated the cells with deuterium-labeled serine
(D3-serine) and found that hypoxia promoted a signiﬁcant increase in
the D3-serine pool in dihydroceramides but a decrease in the D3-serine
pool in ceramides (Fig. 1E), thus conﬁrming that the hypoxia-induced in-
crease in ceramides does not originate from de novo synthesis.
To testwhether hypoxia-induced ceramide accumulation instead re-
sulted from hydrolysis of sphingomyelin, we used siRNA to inhibit acid
sphingomyelinase (Smpd1) and neutral sphingomyelinase (Smpd2) in
HL-1 cardiomyocytes. Importantly, we showed that inhibiting Smpd1
completely blocked ceramide accumulation during hypoxia, whereas
blocking Smpd2 did not have any effect (Fig. 1F). Thus, our results sug-
gest that acid sphingomyelinase mediates the ceramide accumulation
induced by hypoxia in cardiomyocytes.Next, we usedmicewith a heterozygousmutation in Smpd1 to test if
partial inhibition of acid sphingomyelinase would reduce ceramide ac-
cumulation in the post-ischemic heart. Smpd1+/− mice had normal
levels of cardiac glycerolipids and sphingolipids under baseline condi-
tions (Fig. S1). By comparing ceramide species in hearts from WT and
Smpd1+/−mice before and 24 h after an induced myocardial infarction,
we showed that the ischemia-induced accumulation of all ceramide
species in WT hearts was signiﬁcantly reduced in Smpd1+/− hearts,
with the exception of the palmitate- andmyristate-derived 24:0 species
(Fig. 2A and B). Thus, ischemia-induced cardiac ceramide accumulation
can be reduced by targeting acid sphingomyelinase.
We also assessed the cardiac function ofWT and Smpd1+/−mice be-
fore and after an induced myocardial infarction. There were no differ-
ences in stroke volume, ejection fraction or cardiac output between
the groups under baseline conditions nor, surprisingly, 24 h, 72 h and
4 weeks after an induced myocardial infarction (Fig. 2C). In addition,
we did not observe any difference in survival of these mice for up to
30 days after an induced myocardial infarction (Fig. 2D). Thus, in our
Fig. 2. Inactivation of acid sphingomyelinase (Smpd1) reduces ischemia-induced cardiac ceramide accumulation but does not affect heart function. (A–B) Concentrations of d18:1
palmitate-derived (A) and d16:1 myristate-derived (B) ceramide species in WT and Smpd1+/−mice at baseline and 24 h after an induced myocardial infarction (MI) (n= 5–6). Data
are mean ± SEM. #P b 0.01 vsWT baseline ⁎P b 0.05, ⁎⁎P b 0.01 vsWT post MI. (C) Echocardiographic analysis of WT and Smpd1+/−mice at baseline and after an induced MI (n= 9 at
baseline; n= 15–20 at 24 h; n = 7–9 at 72 h; n= 6–7 at 4 weeks). ⁎P b 0.05, ⁎⁎P b 0.01 and ⁎⁎⁎P b 0.001 vsWT baseline; ⁎P b 0.05, ⁎⁎P b 0.01 and ⁎⁎⁎P b 0.001 vs Smpd1+/− baseline.
(D) Kaplan–Meier curve showing survival of WT and Smpd1+/−mice after an induced MI (n= 15–21). Data are analyzed using the log-rank test and P= 0.33.
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tion does not result in improved heart function and survival.
4. Discussion
In this study, we showed that ceramide accumulation associates
with heart function in the human post-ischemic heart and, importantly,
that the increase in ceramides appears to be mediated by acid
sphingomyelinase and not by de novo sphingolipid synthesis. However,
we found that inhibiting acid sphingomyelinase in mice does not result
in improved heart function or survival after an induced myocardial in-
farction despite reducing ischemia-induced ceramide accumulation.
Targeting cardiac ceramide accumulation by inhibition of de novo
sphingolipid synthesis has emerged as a potential strategy to improve
heart function in obesity and diabetes. Pharmacological inhibition of
serine palmitoyltransferase, for example, has been shown to prevent
cardiac toxicity caused by increased lipid uptake and excess ceramides
in a mouse model of dilated cardiomyopathy [6]. However, although de
novo sphingolipid synthesis may be enhanced in the post-ischemic
heart, our results from heart biopsies and cardiomyocytes indicate thatischemia/hypoxia-induced cardiac ceramide accumulation is indepen-
dent of the sphingolipid de novo synthesis pathway but instead results
from hydrolysis of sphingomyelin catalyzed by acid sphingomyelinase.
Indeed, it is known that the enzyme catalyzing ceramide synthesis from
dihydroceramides is oxygen dependent [7], and thus it is unlikely that
de novo synthesis of ceramides would occur in ischemic tissue [8].
Targeting acid sphingomyelinase in the heartwould represent a novel ap-
proach to reduce cardiac ceramide accumulation.
We used mice with a partial deﬁciency in acid sphingomyelinase to
test the hypothesis that limiting ceramide accumulation after amyocar-
dial infarction would improve cardiac function and outcome. However,
contrary to our expectations, cardiac function and outcome following a
myocardial infarction in Smpd1+/− mice were not improved despite
reduced ceramide accumulation compared with WT mice. We used
Smpd1+/− mice as they have normal cardiac ceramide levels under
baseline conditions. However, because they have 50% of normal acid
sphingomyelinase activity [9], ischemia-induced ceramide accumula-
tion is not entirely abolished in thesemice. It is plausible that the reduc-
tion of ceramides was not robust enough to counteract the effects of
this multifactorial pathological process, and we cannot rule out the
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in impaired cardiac function. Furthermore, although long-chained
ceramides were efﬁciently reduced in the Smpd1+/− mice, very long-
chained ceramides were reduced to a lesser extent. Very long-chained
ceramides may be more harmful than long and medium-chained
ceramides [4,10], and we cannot exclude the possibility that these
species preferentially mediate the harmful effects on heart function in
our mouse model. An additional limitation to the study is that the
Smpd1+/− mouse model is a global partial deﬁciency model, and any
differences in heart function or outcome after a myocardial infarction
could potentially be counteracted or enhanced by systemic effects.
In conclusion, our study reveals that ceramide accumulation in the
post-ischemic heart is mediated by acid sphingomyelinase. However,
inhibiting acid sphingomyelinase in mice does not result in improved
heart function or survival after an inducedmyocardial infarction despite
reducing ischemia-induced ceramide accumulation. Further investiga-
tions are therefore needed to determine the potential of targeting cer-
amide accumulation as a treatment for ischemic heart disease.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yjmcc.2016.02.019.
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